Labetalol Pharmakern (Labetalol Hydrochloride)

Labetalol blocks both β‑adrenergic (β1 and β2) and α1‑adrenergic receptors. β‑blockade reduces heart rate and contractility, decreasing cardiac output, while α1‑blockade causes vasodilation by relaxing peripheral vessels. The combined effect lowers systemic vascular resistance and overall blood pressure.

The dose of Labetalol Pharmakern is individualized by the prescribing clinician based on the severity of hypertension, patient weight, renal and hepatic function, and response to therapy. Dosing regimens are adjusted in a controlled setting to achieve target blood‑pressure goals while avoiding rapid over‑correction.

Safety data for intravenous labetalol in pregnancy are limited, and the product lacks a definitive pregnancy‑category assignment. Clinicians weigh potential benefits against risks, and labetalol is generally reserved for severe cases where alternative therapies are unsuitable. Breastfeeding considerations should follow local guidelines and professional judgment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Labetalol’s dual α‑ and β‑blocking profile distinguishes it from agents that target only one receptor class. Compared with pure β‑blockers, it offers additional vasodilation, reducing the risk of reflex tachycardia. Relative to calcium‑channel blockers, it provides more direct heart‑rate control, making it useful in acute, high‑risk hypertension.

Labetalol Pharmakern should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from moisture and direct sunlight, and avoid freezing. Follow any specific manufacturer instructions on the label for optimal stability.

The product is administered intravenously by a healthcare professional. It is typically given as a slow infusion or intermittent bolus, with continuous blood‑pressure monitoring. The infusion rate is adjusted according to the patient’s hemodynamic response and target blood‑pressure parameters.

Serious adverse events include profound hypotension, bronchospasm in patients with reactive airway disease, hepatic injury, and cardiac conduction disturbances such as heart block. Prompt recognition of these signs and immediate medical intervention are essential to prevent complications.

Labetalol is contraindicated in patients with known hypersensitivity to labetalol or any component of the formulation, severe bradycardia, advanced heart block without a pacemaker, and uncontrolled asthma or severe chronic obstructive pulmonary disease. Caution is also advised in patients with hepatic impairment.